Search research articles
Contact Us
Filters
Showing results (81-90 of 418) with videos related to
Page
of 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
Andreas Michael Schmitt, James Larkin, Sapna P Patel
Expert Opinion on Pharmacotherapy
|
May 23, 2015
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Juliet Richman, Juan Martin-Liberal, Stefan Diem, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2022
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont <i>et al</i>
Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, et al.
Expert Opinion on Pharmacotherapy
|
April 27, 2019
Current and emerging systemic therapies for cutaneous metastatic melanoma
Robert Mason, Lewis Au, Alvaro Ingles Garces, et al.
Expert Review of Anticancer Therapy
|
April 16, 2020
Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy
Isla Leslie, Laura Amanda Boos, James Larkin, et al.
The International Journal on Drug Policy
|
April 4, 2025
Prioritising research on marketing and consumption of No and Low (NoLo) alcoholic beverages in Ireland
Emeka W Dumbili, Paula Leonard, James Larkin, et al.
Lancet (London, England)
|
December 7, 2020
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric-Bernstam, James Larkin, Josep Tabernero, et al.
Nature
|
March 5, 2024
Personalized cancer care can't rely on molecular testing alone
James Larkin, Chloe Beland, Sivatharshini Ramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2015
Translational implications of tumor heterogeneity
Mariam Jamal-Hanjani, Sergio A Quezada, James Larkin, et al.
Expert Review of Anticancer Therapy
|
January 9, 2025
Current and emerging treatment options for BRAFV600-mutant melanoma
Anadil Javaid, Tobias Peres, Javier Pozas, et al.
Page
of 42
Search research articles
Search
Showing results (81-90 of 418) with videos related to
Sort By:
Page
of 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2024
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
Andreas Michael Schmitt, James Larkin, Sapna P Patel
Expert Opinion on Pharmacotherapy
|
May 23, 2015
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Juliet Richman, Juan Martin-Liberal, Stefan Diem, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2022
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont <i>et al</i>
Jeffrey Weber, Mario Mandala, Paolo Antonio Ascierto, et al.
Expert Opinion on Pharmacotherapy
|
April 27, 2019
Current and emerging systemic therapies for cutaneous metastatic melanoma
Robert Mason, Lewis Au, Alvaro Ingles Garces, et al.
Expert Review of Anticancer Therapy
|
April 16, 2020
Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy
Isla Leslie, Laura Amanda Boos, James Larkin, et al.
The International Journal on Drug Policy
|
April 4, 2025
Prioritising research on marketing and consumption of No and Low (NoLo) alcoholic beverages in Ireland
Emeka W Dumbili, Paula Leonard, James Larkin, et al.
Lancet (London, England)
|
December 7, 2020
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric-Bernstam, James Larkin, Josep Tabernero, et al.
Nature
|
March 5, 2024
Personalized cancer care can't rely on molecular testing alone
James Larkin, Chloe Beland, Sivatharshini Ramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2015
Translational implications of tumor heterogeneity
Mariam Jamal-Hanjani, Sergio A Quezada, James Larkin, et al.
Expert Review of Anticancer Therapy
|
January 9, 2025
Current and emerging treatment options for BRAFV600-mutant melanoma
Anadil Javaid, Tobias Peres, Javier Pozas, et al.
Page
of 42